Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Big 3 Generic Maker Curbing Valsartan Shipments amid India Lockdown
Towa Pharmaceutical, one of Japan’s Big Three generic makers, is curbing its shipments for the hypertension medicine valsartan and its combination drugs as it has been unable to secure API supplies from India amid the COVID-19 pandemic. In its notification…
To read the full story
Related Article
- API/Intermediate Imports from India Still Stalled, Traders’ Group Calls for Govt Schemes
June 4, 2020
- After Valsartan, Towa Now Curbing Clindamycin Supplies as India Lockdown Continues
April 13, 2020
- Indian Export Restriction Lifted, but Japan Imports Still Stalled
April 10, 2020
- India Lockdown Derails Japan-Bound APIs, Intermediate Exports
March 30, 2020
BUSINESS
- Takeda’s XFG-Targeted COVID Jab Approved in Japan
August 27, 2026
- Meiji Wins Japan Approval for NB.1.8.1-Adapted COVID Vaccine
August 27, 2026
- Japan Pharma Market Seen Topping 11 Trillion Yen by 2035: Fuji Keizai
August 26, 2026
- Belite Bio Eyes Japan Filing for Stargardt Drug within 3 Months
August 26, 2026
- Sandoz to Sell, Distribute G-Lasta Biosimilar in Japan
August 26, 2026
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…